George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Why don't we just leave it to the experts that we have trusted our money with to fully analyse and report the data instead of wannabe professors making unhelpful statements about something they're guessing at FFS. Have some patience
Ndn71 filtered, like the sound of your own voice too much, come out with ridiculous statements like the one @ 18.19, reply to your own posts if nobody else does, very strange.
I knew this thread would take a Tern for the worse
Cheers
Axe can you add me please, I've had my 3 jabs now, so it's safe for me to travel to Pompey
All the best to you Pdub
Many moons ago Fortune said getting the acid will be no problem, due to it being waste material from other local mining/leaching processes.
£20 p/s by a european company, all done and dusted by June
Loose lips, sink ships
Protein production mentioned, probably not about us, but highlights the need for stockpiling.
https://uk.yahoo.com/news/uk-neglecting-future-pandemic-threat-084458959.html
Don't take it to heart mush, keep hold of those shares tightly. I'm in a similar position to you, I can't add anything to the discussion due to the quality of posters on this forum. I do however know that everything is going to work out mighty fine, I might even pop down the M27 and explain at a later date. Can you add me to the party list please Axe.
Alarming stats coming out of rest of Europe
https://c.newsnow.co.uk/A/1102249561?-49183:36126
Why would Polygon stop now, they're acting on the latest news.
A friend who works in health research read the report and highlighted the paragraph below.
On September 4, 2020, the study was modified to stop enrolling participants with severe COVID-19 who required high-flow oxygen and to exclude people who required non-invasive or invasive mechanical ventilation. These changes were made after the study’s Data and Safety Monitoring Board (DSMB) noted a greater rate of severe adverse events, particularly worsening of respiratory status, among participants requiring high-flow oxygen at enrollment who received interferon beta-1a compared to those who did not receive interferon beta-1a. The ACTT-3 investigators speculate that interferon may have increased the inflammatory response, leading to more severe respiratory disease in these participants. However, the investigators note that this worse outcome might have been influenced by baseline imbalances between the interferon and control groups.
Words used such as "might "and " speculate" show that they don't really know.
No conspiracy around the publishing date, it is quite normal to be this length of time from results.
Here's a more cautious review about the 'magic pill'
https://c.newsnow.co.uk/A/1098246812?-49183:36126
wpa5, you've hit the nail on the head, everybody at Synairgen are extremely busy.
Eye watering figures mentioned in this article, hold for gold. https://c.newsnow.co.uk/A/1094390412?-49183:36126
Each to their own, seen the same on many shares, seems to be standard practice. Good luck anyway